RTP Mobile Logo
Myelodysplastic Syndromes Update, Issue 1, 2017 (Video Program)
Released August 2017

Proceedings from video interviews with clinical investigators Drs Mikkael A Sekeres and Steven D Gore featuring the latest research developments in the management of myelodysplastic syndromes. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of hematologic cancers.

    The clinical management of myelodysplastic syndromes remains a challenge from both a diagnostic and treatment standpoint, despite recent gains made in the understanding of this heterogeneous disease. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Myelodysplastic Syndromes Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.


    • Recognize the key cancer-defining features of MDS, and counsel patients accordingly regarding their prognosis, treatment goals and options.
    • Appraise the role of molecular testing for MDS to facilitate diagnosis, prognostication and treatment decision-making.
    • Formulate a treatment algorithm for patients with lower- and higher-risk MDS, considering patient- and disease-related factors, including cytogenetic abnormalities.
    • Consider the available efficacy and safety data with the use of lenalidomide in patients with low- to intermediate-risk MDS with and without del(5q), and identify patients with MDS appropriate for this treatment.
    • Evaluate the potential advantages of orally administered hypomethylating agents compared to standard parenteral administration of these drugs.
    • Ascertain the utility of novel agents, such as luspatercept, in the management of anemia in patients with MDS, and consider its future role in clinical management.
    • Recall promising investigational agents (eg, anti-PD-1/anti-PD-L1 monoclonal antibodies, venetoclax, IDH1/2 inhibitors) and combination strategies, and counsel appropriately selected patients regarding clinical trial enrollment.
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Mikkael A Sekeres, MD, MS
    Professor of Medicine
    Vice Chair for Clinical Research
    Director, Leukemia Program
    Professor of Medicine
    Cleveland Clinic
    Taussig Cancer Institute
    Cleveland, Ohio

    Advisory Committee: Celgene Corporation, Daiichi Sankyo Inc.

    Steven D Gore, MD
    Professor of Internal Medicine (Hematology)
    Yale Cancer Center
    Director, Hematologic Malignancies
    New Haven, Connecticut

    Advisory Committee and Consulting Agreement: Celgene Corporation; Contracted Research: Celgene Corporation, Genentech BioOncology.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by an educational grant from Celgene Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2017
    Expiration date: August 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):